KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Share-based Compensation (2016 - 2025)

Gilead Sciences' Share-based Compensation history spans 17 years, with the latest figure at $230.0 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 3.6% year-over-year to $230.0 million; the TTM value through Dec 2025 reached $894.0 million, up 7.07%, while the annual FY2025 figure was $894.0 million, 7.07% up from the prior year.
  • Share-based Compensation reached $230.0 million in Q4 2025 per GILD's latest filing, roughly flat from $230.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $230.0 million in Q3 2025 to a low of $130.0 million in Q1 2022.
  • Average Share-based Compensation over 5 years is $188.4 million, with a median of $192.5 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: dropped 6.47% in 2022, then rose 26.92% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $159.0 million in 2021, then increased by 9.43% to $174.0 million in 2022, then rose by 15.52% to $201.0 million in 2023, then grew by 10.45% to $222.0 million in 2024, then grew by 3.6% to $230.0 million in 2025.
  • Per Business Quant, the three most recent readings for GILD's Share-based Compensation are $230.0 million (Q4 2025), $230.0 million (Q3 2025), and $225.0 million (Q2 2025).